Funding for this research was provided by:
Janssen Scientific Affairs (N/A)
Text and Data Mining valid from 2020-04-08
Received: 19 December 2019
Accepted: 18 March 2020
First Online: 8 April 2020
Ethics approval and consent to participate
: The use of the Optum EHR database was reviewed by the New England Institutional Review Board (IRB) and was determined to not constitute research involving human subjects according to 45 Code of Federal Regulations 46.102(f) and therefore deemed exempt from board oversight.
: Not applicable.
: C. I. Coleman has received grant funding and consultancy fees from Janssen Scientific Affairs LLC, Titusville, NJ and Bayer AG, Berlin, Germany and speaker fees from Medscape Inc.V. Ashton is an employee of Janssen Scientific Affairs LLC, Titusville, NJ.M. Palladino is an employee of Janssen Pharmaceuticals Inc., Titusville, NJ.S. Thompson serves on the Xarelto Speaker’s Bureau for Janssen Pharmaceuticals, Titusville, NJ and advisory boards for Salix Pharmaceuticals, Bridgewater, NJ.O. S. Costa and T. J. Bunz have no declarations-of-interest.